FrontAct

FrontAct is a Swiss biotechnology company specializing in the discovery and development of next-generation therapeutics targeting G protein-coupled receptors (GPCRs). Spun out from the University of Geneva and EPFL, the company utilizes a proprietary platform that combines structural bioinformatics with advanced biosensor technology to identify functionally selective, or "biased," ligands. This approach aims to maximize therapeutic efficacy while minimizing off-target side effects by precisely modulating specific signaling pathways within the GPCR family. FrontAct's current research focus includes addressing unmet needs in metabolic disorders, inflammatory diseases, and oncology through the development of novel small molecule candidates. The company's technology leverages high-resolution structural data and computational modeling to accelerate the drug discovery process for traditionally difficult-to-target receptors.